Abstract: A biometric information display apparatus (30) for displaying a measurement result obtained by measuring a biometric signal, includes a maximum value calculation unit (63) configured to calculate a maximum value of the measurement result in a certain period of time for at least one of blocks into which a measurement area, in which the biometric signal is measured, is divided, a determination unit (64) configured to determine whether a measurement value in the at least one of blocks is greater than or equal to a threshold value obtained by multiplying the maximum value by a fractional value, the fractional value being determined in advance, and a display control unit configured to display, in response to an occurrence of an event in which the measurement value is determined to be greater than or equal to the threshold value, the measurement result in such a manner as to indicate the occurrence of the event.

Abstract: A non-transitory computer-readable recording medium has stored therein an evaluating program for causing a computer to execute a process including: specifying a wall of an inspection target in two or more moving images being obtained by photographing two types of cross sections of the inspection target, the two types of cross sections being orthogonal to each other; evaluating photographing quality of each of a plurality of first divisional regions obtained by dividing a region corresponding to the wall specified in a first image related to a first cross section among the two or more moving images; and evaluating photographing quality of each of a plurality of second divisional regions obtained by dividing a region corresponding to the wall specified in a second image related to a second cross section among the two or more moving images, the second cross section being different from the first cross section.

Abstract: The object of the present invention is to provide a nucleic acid agent that is efficiently delivered to the nervous system, for example, the central nervous system to which drug delivery can be prevented by BBB, and produces an antisense effect on the target transcriptional product at the delivery site, and a composition comprising the same. In an embodiment, the present invention provides a double-stranded nucleic acid complex formed by annealing a first nucleic acid strand that hybridizes to a part of a target transcriptional product and has an antisense effect on the target transcriptional product, and a second nucleic acid strand that comprises a base sequence complementary to the first nucleic acid strand and is bound to a C22-35 alkyl group optionally substituted with a hydroxy group or an analog thereof.

Abstract: A biomagnetic field measurement processing apparatus includes circuitry; and a memory storing computer-executable instructions that cause the circuitry to execute reconfiguring a current signal from a biomagnetic field signal; extracting a current component from the current signal; and based on the extracted current component, adding to each other at least two current waveforms among current waveforms of a plurality of inward currents that are current components directed toward a nerve axon from around the nerve axon, or adding to each other at least two current waveforms among current waveforms of a plurality of inward currents that are current components directed toward a muscle fiber from around the muscle fiber, and generating a current waveform to be displayed on a display device, according to the at least two current waveforms added to each other.

Abstract: An object of the present invention is to provide a method of conveniently producing a genetically modified non-human mammal with high efficiency using a CRISPR-Cas9 system and particularly a production method whereby gene knock-in can be achieved with high efficiency regardless of the gene size. The method of producing a genetically modified non-human mammal comprises introducing a Cas9 protein, a crRNA fragment comprising a nucleotide sequence complementary to a target DNA region, and a tracrRNA fragment into a non-human mammalian oocyte to genetically modify the target DNA.

Abstract: A medical diagnostic apparatus includes a receiver circuit that receives three-dimensional data of an eye, and processing circuitry configured to segment the three-dimensional data into regions that include a target structural element and regions that do not include the target structural element to produce a segmented three-dimensional data set. The segmenting is performed using a plurality of segmentation algorithms. Each of the plurality of segmentation algorithms is trained separately on different two-dimensional data extracted from the three-dimensional data. The processing circuitry is further configured to generate at least one metric from the segmented three-dimensional data set, and evaluate a medical condition based on the at least one metric.

Abstract: A double-stranded nucleic acid complex is a double-stranded nucleic acid complex including a first nucleic acid strand and a second nucleic acid strand bonded to each other, the second nucleic acid strand including a complementary region having a base sequence complementary to the first nucleic acid strand; the first nucleic acid strand including natural nucleosides and non-natural nucleosides; some of the nucleosides in at least one nucleic acid strand selected from the group consisting of the first nucleic acid strand and the second nucleic acid strand being bonded together by bonds including asymmetric phosphorus atoms; and absolute configurations of the asymmetric phosphorus atoms being regulated.

Abstract: A biomagnetism measurement apparatus includes a memory and a processor configured to set a curved surface as a region-of-interest based on a morphological image including a portion to be evaluated of a subject, the morphological image being acquired by an image acquisition apparatus, and the curved surface being a surface on which an anterior-posterior position of the subject changes in a cranial-caudal direction and in a left-right direction along a position of a nerve to be evaluated. The processor is further configured to estimate current distribution in the region-of-interest based on magnetic data, the magnetic data being acquired by measuring a magnetic field with a magnetic measurement instrument, and the magnetic field being generated by an electrical activity of a nerve in the portion to be evaluated.

Abstract: A biometric information display device includes a display controller configured to display a morphological image indicative of a morphology of a subject, on a display, an input controller configured to receive a designation of a specified position on the morphological image, a pathway generating section configured to generate a pathway based on the specified position on the morphological image, and a current extracting section configured to extract current components at a plurality of positions along the pathway, based on current information reconstructed based on magnetic field measurement data generated by the subject. The display controller displays the current components extracted along the pathway on the display.

Abstract: The present invention provides a composition and a method for efficiently delivering a nucleic acid agent to the central nervous system and/or the retina and bringing about antisense effects. Provided is a composition for reducing the expression level of a target transcription product in the central nervous system and/or retina of a subject, the composition including a nucleic acid complex that includes a first nucleic acid strand and a second nucleic acid strand, wherein: the first nucleic acid strand comprises a base sequence capable of hybridizing with at least part of the target transcription product and has an antisense effect on the target transcription product; the second nucleic acid strand comprises a base sequence complementary to the first nucleic acid strand and is conjugated to tocopherol, cholesterol, or an analog thereof; and the first nucleic acid strand is annealed to the second nucleic acid strand.

Abstract: The present invention addresses the problem of providing a muscle activity measurement device and a muscle activity measurement method which make it possible to measure the muscle activity of an object to be sensed with increased accuracy. The muscle activity measurement device is provided with a magnetic sensor unit which senses a magnetic field generated from a living body. The muscle activity measurement device identifies an installed direction of the muscle activity measurement device, and includes an indication, on a surface of a container, which comprises identification information for installing the muscle activity measurement device in such a way that a magnetism sensing direction X of the magnetic sensor unit and the direction in which the muscle fibers of the living body as the object to be sensed extend are substantially orthogonal to each other.

Abstract: The present invention relates to an antibacterial composition and the like having antibacterial property against Acinetobacter. The present invention provides an antibacterial composition comprising a complex of lysozyme and chitosan bound together, with antibacterial property against Acinetobacter; and a pharmaceutical composition for treating or preventing an Acinetobacter infection, comprising a complex of lysozyme and chitosan bound together.

Abstract: A biomagnetic measurement apparatus includes a table on which a subject is placed; a biomagnetic detector configured to detect a biomagnetic field of the subject; a supporter configured to support a detection target region from which the biomagnetic field of the subject is detected; a radiation detector provided below the supporter; and a position changer configured to change relative positions of the biomagnetic detector and the detection target region. The supporter has a surface shape that corresponds to a surface of the biomagnetic detector.

Abstract: A biological-data processing apparatus includes a processor; and a memory that includes instructions, which when executed, cause the processor to execute performing an addition-averaging process every time an addition count of biological data reaches a predetermined count, the biological data being measured in response to a trigger signal associated with a stimulus applied to one or more parts; storing, in a storage, addition-average data resulting from the addition-averaging process performed for each of the stimulated one or more parts, in association with the addition count in the addition-average data; and performing a biological data process based on the biological data, by using the addition-average data corresponding to each of the stimulated one or more parts, the addition-average data being acquired by referring to the storage based on the addition count that is specified.

Abstract: A nucleic acid complex that exhibits an excellent antisense effect in the skeletal muscle and/or heart muscle, and a composition for treating or preventing a muscle disease that develops in the skeletal muscle, heart muscle, and the like having the nucleic acid complex as an active ingredient is disclosed. Also provided is a double-stranded nucleic acid complex in which a first nucleic acid strand that hybridizes to the transcription product of a target gene and has an antisense effect on the transcription product is annealed with a second nucleic acid strand that has a base sequence complementary to the first nucleic acid strand and is bound to cholesterol or analog thereof.

Abstract: One of the purposes of the present invention is to provide a method for producing a gene-edited tissue stem cell in an undifferentiated state within a short period of time. Another one of the purposes of the present invention is to provide a method for treating and/or preventing a disease using a gene-edited tissue stem cell in an undifferentiated state. A gene-edited tissue stem cell is produced by a method comprising a step for editing the gene sequence of a target gene in tissue stem cells, and a step for selecting the tissue stem cells having an edited gene sequence, and optionally, further comprising a step for adding a tag to the gene sequence of the target gene and/or a step for activating gene expression of the target gene in the tissue stem cells. The tissue stem cell thus produced is used in treating/preventing diseases.

Abstract: An atrial fibrillation analysis device includes: a hardware processor that: acquires P-wave data from only one of either: a first electrocardiogram in a lead of one direction on a plane including a body-axis direction and a left-right direction with respect to a subject, or a second electrocardiogram in leads of two directions orthogonal to each other on the plane; extracts P-wave fragments from the acquired P-wave data; and analyzes a possibility of development of atrial fibrillation based on at least one of a number of the P-wave fragments and a duration of the P-wave fragments.

Abstract: The present inventors have clarified that activin has an activity of promoting the proliferation of MSCs and an activity of promoting the regeneration of meniscus or cartilaginous tissue without affecting differentiation multipotency. Further, the present inventors have also found that the use of activin makes it possible to treat and prevent meniscus damage or cartilage disorders, including suppression of degenerative degeneration of cartilage and pain.

Abstract: A clinical trial matching apparatus according to an embodiment includes processing circuitry. The processing circuitry receives patient information. The processing circuitry retrieves a clinical trial matching the patient from clinical trials based on the patient information, by referring to storage circuitry that stores data for associating a clinical trial in which medication conditions are set with the results of the clinical trial, for the clinical trials. The processing circuitry presents the retrieved clinical trial. The processing circuitry collects, and stores in the storage circuitry, the results obtained by conducting the retrieved clinical trial on the patient and patient's clinical information. The processing circuitry updates the conditions of the retrieved clinical trial based on the clinical information, when there is clinical information that can identify a significant difference in drug efficacy in the collected clinical information.

Abstract: The present invention provides a fusion protein of an antigen-binding protein and a fluorescent protein or a fluorescence-labeled tag protein. The present invention provides a fusion protein of an antigen-binding protein and a fluorescent protein or a fluorescence-labeled tag, wherein the antigen-binding protein is an antigen-binding protein having a helix structure or a ?-sheet structure at a terminus, the fluorescent protein or the fluorescence-labeled tag is a fluorescent protein or a fluorescence-labeled tag having a helix structure or a ?-sheet structure at a terminus, and the helix at the terminus and the helix at the terminus are linked, or the ?-sheet structure at the terminus and the ?-sheet structure at the terminus are linked.